Evommune Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-42938 Evommune, Inc. (Exact Name of Registrant as Specified in its Charter) 85-0742575(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 1891 Page Mill RoadPalo Alto, CA(Address of principal executive offices) (925) 247-4481(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 4, 2026, the registrant had 36,292,113 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents Item 1.Financial Statements (unaudited)5Condensed Consolidated Balance Sheets (unaudited)5Condensed Consolidated Statements of Operations (unaudited)6Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)(unaudited)7Condensed Consolidated Statements of Cash Flows (unaudited)8Notes to Condensed Consolidated Financial Statements (unaudited)9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24 PART II.OTHER INFORMATION24 Item 1.Legal Proceedings24Item 1A.Risk Factors25Item 2.Unregistered Sales of Equity Securities and Use of Proceeds25Item 3.Defaults Upon Senior Securities25Item 4.Mine Safety Disclosures25Item 5.Other Information26Item 6.Exhibits27Signatures28 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains express or implied forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) andSection 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based on ourmanagement’s belief and assumptions and on information currently available to our management. Although we believe that theexpectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our futureoperational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause ouractual results, performance or achievements to be materially different from any future results, performance or achievementsexpressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Qinclude, but are not limited to, statements about: •the success, cost and timing of our product development activities and clinical trials of our most-advanced productcandidates, EVO756 and EVO301, and any future product candidates;•the characteristics and potential advantages of our product candidates;•our need to raise additional funding before we can expect to generate any revenues from product sales;•our ability to obtain regulatory approval for our current or future product candidates that we may identify or develop;•our ability to ensure adequate supply of our current or future product candidates;•our ability to maintain third-party relationships necessary to conduct our business;•our heavy dependence upon the success of our research to generate and advanc